Biological characterization of stem cell present in mobilized peripheral blood of CML patients.
Tsukamoto As(System Biosciences (United States)), AB Deisseroth(The University of Texas MD Anderson Cancer Center), Christopher L. Reading(Novartis (China)), Francesco Frassoni(Ospedale Policlinico San Martino), Justin LaPorte(Novartis (China)), Isabel Cunningham(Novartis (China)), RS Negrin(Stanford University), Cécile Gorin(Novartis (China)), K G Blume(Novartis (China)), Angelo Michele Carella(San Antonio College)
PubMed
January 1, 1994
Cited by 8
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
|The Journal of Experimental Medicine|1991|623